Ariane Germeyer

Ariane Germeyer

Auto-generated profile, based on publicly available information

Ariane Germeyer

Heidelberg University Women´s Hospital, Department of Gynecologic Endocrinology and Fertility Disorders 1

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
MWMichael Von Wolff
Michael Von Wolff
AGAriane Germeyer
Ariane Germeyer
BBBettina Böttcher
Bettina Böttcher
IMIsotta Martha Magaton
Isotta Martha Magaton
IMIrene Marcu
Irene Marcu
SWSusanna Weidlinger
Susanna Weidlinger
Background: Cytotoxic treatments such as chemo- and radiotherapy and immune therapies are required in cancer diseases. These therapies have the potential to cure patients but may also have an impact on gonadal function and, therefore, on fertility. Consequently, fertility preservation treatments such as freezing of gametes and gonadal tissue might be required. However, as detailed data about the necessity to perform fertility preservation treatment are very limited, this study was designed to fill this data gap. Objective: Primary objective of this study is to analyze the impact of cancer therapies and chemotherapies on the ovarian reserve and sperm quality. Secondary objectives are to analyze the (1) impact of cancer therapies and chemotherapies on other fertility parameters and (2) probability of undergoing fertility preservation treatments in relation to specific cancer diseases and treatment protocols and the probability to use the frozen gametes and gonadal tissue to achieve pregnancies. Methods: First, previously published studies on the gonadotoxicity of chemo- and radiotherapies among patients with cancer will be systematically analyzed. Second, a prospective cohort study set up by approximately 70 centers in Germany, Switzerland, and Austria will collect the following data: ovarian function by analyzing anti-Müllerian hormone (AMH) concentrations and testicular function by analyzing sperm parameters and total testosterone immediately before and around 1 year after gonadotoxic therapies (short-term fertility). A follow-up of these fertility parameters, including history of conceptions, will be performed 5 and 10 years after gonadotoxic therapies (long-term fertility). Additionally, the proportion of patients undergoing fertility-preserving procedures, their satisfaction with these procedures, and the amount of gametes and gonadal tissue and the children achieved by using the frozen material will be analyzed. Third, the data will be merged to create the internet-based data platform FertiTOX. The platform will be structured in accordance with the ICD (International Classification of Diseases) classification of cancer diseases and will be easily be accessible using a specific App. Results: Several funding bodies have funded this study. Ten systematic reviews are in progress and the first one has been accepted for publication. All Swiss and many German and Austrian ethics committees have provided their approval for the prospective cohort study. The study registry has been set up, and a study website has been created. In total, 50 infertility centers have already been prepared for data collection, which started on December 1, 2023. Conclusions: The study can be expected to bridge the data gap regarding the gonadotoxicity of cancer therapies to better counsel patients about their infertility risk and their need to undergo fertility preservation procedures. Initial data are expected to be uploaded on the FertiTOX platform in 2026. Trial Registration: ClinicalTrials.gov NCT05885048; https://clinicaltrials.gov/study/NCT05885048 International Registered Report Identifier (IRRID): DERR1-10.2196/51145

17 September 2013 in Human Reproduction
Verified
Journal Article
Open access
PDF file
MWMichael Von Wolff
Michael Von Wolff
SRS. Rosner
S. Rosner
AGA. Germeyer
A. Germeyer
JJJ. Jauckus
J. Jauckus
GGG. Griesinger
G. Griesinger
TST. Strowitzki
T. Strowitzki
Does intrauterine application of diluted seminal plasma (SP) at the time of ovum pick-up improve the pregnancy rate by ≥14% in IVF treatment? Intrauterine instillation of diluted SP at the time of ovum pick-up is unlikely to increase the pregnancy rate by ≥14% in IVF. SP modulates endometrial function, and sexual intercourse around the time of embryo transfer has been suggested to increase the likelihood of pregnancy. A previous randomized double-blind pilot study demonstrated a strong trend towards increased pregnancy rates following the intracervical application of undiluted SP. As this study was not conclusive and as the finding could have been confounded by sexual intercourse, the intrauterine application of diluted SP was investigated in the present trial. A single-centre, prospective, double-blind, placebo-controlled, randomized, superiority trial on women undergoing IVF was conducted from April 2007 until February 2012 at the University Department of Gynaecological Endocrinology and Reproductive Medicine, Heidelberg, Germany. The study was powered to detect an 14% increase in the clinical pregnancy rate and two sequential tests were planned using the Pocock spending function. At the first interim analysis, 279 women had been randomly assigned to intrauterine diluted SP (20% SP in saline from the patients' partner) (n = 138) or placebo (n = 141) at the time of ovum pick-up. The clinical pregnancy rate per randomized patient was 37/138 (26.8%) in the SP group and 41/141 (29.1%) in the placebo group (difference: −2.3%, 95% confidence interval of the difference: −12.7 to +8.2%; P = 0.69). The live birth rate per randomized patient was 28/138 (20.3%) in the SP group and 33/141 (23.4%) in the placebo group (difference: −3.1%, 95% confidence interval of the difference: −12.7 to +6.6%; P = 0.56). It was decided to terminate the trial due to futility at the first interim analysis, at a conditional power of 62%. The confidence interval of the difference remains wide, thus clinically relevant differences cannot reliably be excluded based on this single study. The results of this study cast doubt on the validity of the concept that SP increases endometrial receptivity and thus implantation in humans. Funding was provided by the department's own research facilities. DRKS00004615.

15 February 2018 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
GFGustavo Dias Ferreira
Gustavo Dias Ferreira
ECEdison Capp
Edison Capp
JJJulia Jauckus
Julia Jauckus
TSThomas Strowitzki
Thomas Strowitzki
AGAriane Germeyer
Ariane Germeyer

6 May 2024 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Open access
PDF file
DEDeborah van Eickels
Deborah van Eickels
MSMaren Schick
Maren Schick
AGAriane Germeyer
Ariane Germeyer
SRSabine Rösner
Sabine Rösner
TSThomas Strowitzki
Thomas Strowitzki
BDBeate Ditzen
Beate Ditzen
Purpose: Endometriosis and infertility are associated with impaired partnership and sexuality of the patients, but also of their male partners. Also, endometriosis is one of the most common causes of infertility, resulting in a large overlap of both pathologies. The aim of this study was to determine the association of different predictors of partnership and sexual satisfaction and dyadic effects in couples with endometriosis and infertility. Methods: A cross-sectional study was conducted with n = 62 women with endometriosis and n = 46 partners, including a total of n = 44 couples, some of whom were affected by infertility. The questionnaire included items on partnership, sexuality, depression, social support, and desire for a child. Multiple linear regression and the actor-partner-interdependence-model were used for analysis. Results: Significant dyadic effects only occurred in couples with both endometriosis and infertility. Depression showed a significant negative actor effect in men for partnership satisfaction and a negative actor and partner effect in women for sexuality satisfaction (p < .05). For women, social support showed a significant positive actor effect for partnership satisfaction (p < .05), age showed a significant actor and partner effect for sexuality satisfaction (p < .05). Conclusion: The results show a significant association of endometriosis and infertility with partnership and sexuality satisfaction. Infertility could be a decisive factor. However, the large overlapping of both endometriosis und infertility in many couples support the importance of further studies to differentiate between the both effects. Trial registration: German Clinical Trials Register DRKS00014362 on the 29.03.2018.

1 May 2012 in Journal of Reproductive Immunology
Verified
Journal Article
Closed access
RKR.-J. Kuon
R.-J. Kuon
LWL.-M. Wallwiener
L.-M. Wallwiener
AGA. Germeyer
A. Germeyer
TST. Strowitzki
T. Strowitzki
VDV. Daniel
V. Daniel
BTB. Toth
B. Toth

20 March 2025 in Reproduction and Fertility
Verified
Journal Article
Open access
PDF file
JDJens Erik Dietrich
Jens Erik Dietrich
IVIngrid Cáceres Valcárcel
Ingrid Cáceres Valcárcel
ECEdison Capp
Edison Capp
TSThomas Strowitzki
Thomas Strowitzki
AGAriane Germeyer
Ariane Germeyer
To improve clinical outcomes of human medically assisted reproduction, the transfer of multiple embryos is frequently performed. This leads to high rates of multiple pregnancies. In this study we explored if a cohort of patients can be defined, that benefits from the transfer of two embryos while mitigating the odds of multiple pregnancies by considering female patients’ age, embryo quality and embryo cohort quality. In this retrospective cohort study, clinical pregnancy rate (CPR), live birth rate (LBR) and multiple pregnancy rate (MPR) after fresh single embryo transfers (SETs, n = 245) were compared to those after double embryo transfer (DET, n = 278). Female patient’s age, embryo quality and embryo cohort quality were used to explore clinical outcomes in subgroups. Overall, this study found that compared to SET, DET significantly increased the CPR (33.5 vs 49.6%, adjusted odds ratio (aOR): 2.233, 95% CI: 1.529–3.261, P < 0.001), LBR (24.1 vs 39.2%, aOR: 2.416, 1.605–3.636, P < 0.001) and MPR (0.0 vs 25.4%, P < 0.001). Subgroup analysis based on female age, embryo quality and further stratification based on embryo cohort score revealed that the MPR in all subgroups was high after DET and a subgroup with significantly reduced MPR after DET could not be defined. In conclusion, DETs are associated with high MPRs that cannot be avoided by considering female patients’ age, embryo quality and embryo cohort quality. SET is the most effective way to avoid a multiple pregnancy. Lay summary: This study examined whether it is possible to avoid multiple pregnancies in treatments of assisted reproduction when two embryos are transferred to certain patients. Transferring more than one embryo can increase the chances of pregnancy and live birth but also raises the risk of multiple pregnancies. Multiple pregnancies are linked to health risks for both the mother and the children. Using data from a single clinic, this study explored whether there are specific patients who could benefit from the transfer of two embryos while still having a lower risk of multiple pregnancy. However, the researchers found that DETs consistently lead to high rates of multiple pregnancies, even when factors like the mother’s age, embryo quality and overall embryo cohort quality are considered. The researchers concluded that transferring a single embryo remains the safest approach to prevent multiple pregnancies.